KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Notes Payables (2018 - 2024)

Exact Sciences (EXAS) has disclosed Notes Payables for 5 consecutive years, with $249.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Notes Payables changed N/A to $249.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $249.2 million, a N/A change, with the full-year FY2024 number at $249.2 million, changed N/A from a year prior.
  • Notes Payables was $249.2 million for Q4 2024 at Exact Sciences, roughly flat from $249.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $249.2 million in Q4 2024 to a low of $1.3 million in Q2 2020.
  • A 3-year average of $93.5 million and a median of $1.3 million in 2020 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: soared 217.83% in 2020, then crashed 94.63% in 2021.
  • Exact Sciences' Notes Payables stood at $1.3 million in 2020, then changed by 0.0% to $1.3 million in 2021, then skyrocketed by 18789.54% to $249.2 million in 2024.
  • Per Business Quant, the three most recent readings for EXAS's Notes Payables are $249.2 million (Q4 2024), $249.0 million (Q3 2024), and $248.9 million (Q2 2024).